Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20278663 | 0.86 | MEN1 (0.36) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20278660 | 0.86 | MEN1 (0.38) | MEN1KMT2ARAB9AHPGD | |
| SCHEMBL19484127 | 0.86 | KMT2A (0.48) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20283850 | 0.85 | MEN1 (0.37) | MEN1KMT2ARAB9AHPGD | |
| SCHEMBL20278662 | 0.84 | NPC1 (0.37) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19484133 | 0.84 | KMT2A (0.38) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20278740 | 0.81 | NPC1 (0.32) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL19484146 | 0.78 | TRPV1 (0.40) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL20278616 | 0.77 | TRPV1 (0.31) | ALDH1A1HTT | |
| SCHEMBL20278739 | 0.76 | PDCD1LG2 (0.33) | RAB9AHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180168159-A1 | AGENT FOR CONTROLLING NOXIOUS ARTHROPODS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180168159-A1 | AGENT FOR CONTROLLING NOXIOUS ARTHROPODS | C3AR1, OPRM1, CHRM1 | MEN1 4310/4885KMT2A 4503/4885NPC1 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.